Pages that link to "Q40873316"

The following pages link to Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy (Q40873316):

Displaying 36 items.

• Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer (Q24244156) (← links)
• Systems modeling of anti-apoptotic pathways in prostate cancer: psychological stress triggers a synergism pattern switch in drug combination therapy (Q28536000) (← links)
• Detection and cloning of a protein recognized by anti-human prostate-specific antigen (PSA) antibody in the rat ventral prostate (Q31953978) (← links)
• Identification of dehydroepiandrosterone metabolites formed from human prostate homogenate using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry (Q33425589) (← links)
• Hormonal therapy for metastatic prostate cancer (Q33607625) (← links)
• Secondary hormonal manipulations in hormone refractory prostate cancer (Q33653612) (← links)
• Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy (Q33736837) (← links)
• How is androgen-dependent metastatic prostate cancer best treated? (Q34393961) (← links)
• Hormone-refractory Prostate Cancer (Q34795762) (← links)
• The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer (Q34956110) (← links)
• Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer (Q36113804) (← links)
• Impact of neonatal manipulation of androgen receptor function on endocrine-metabolic programming in the juvenile female rat. (Q37166614) (← links)
• Physiology and endocrinology of hot flashes in prostate cancer (Q37502280) (← links)
• Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles (Q37709535) (← links)
• Molecular mechanisms of androgen action (Q38312948) (← links)
• Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy (Q39568277) (← links)
• Gonadotrophin-releasing hormone agonists. A guide to use and selection (Q40394336) (← links)
• The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase (Q40483542) (← links)
• Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer? (Q40614054) (← links)
• Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification (Q40775613) (← links)
• Stable expression of the human 5alpha-reductase isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors (Q40787267) (← links)
• Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer (Q40944834) (← links)
• Medical approaches in the management of prostatic disease (Q41450497) (← links)
• Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels (Q44381734) (← links)
• Androgen deprivation as a strategy for prostate cancer chemoprevention. (Q53933030) (← links)
• Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer (Q71687184) (← links)
• Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy (Q72090259) (← links)
• Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial (Q72282161) (← links)
• Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance (Q73286328) (← links)
• Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making (Q73290328) (← links)
• Effect of the dual 5α-reductase inhibitor Pnu 157706 on the growth of dunning R3327 prostatic carcinoma in the rat (Q74597862) (← links)
• Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor (Q77666255) (← links)
• A novel molecular modelling study of inhibitors of the 17alpha-hydroxylase component of the enzyme system 17alpha-hydroxylase/17,20-lyase (P-450(17alpha)) (Q78246184) (← links)
• Prostate cancer in the elderly (Q81640912) (← links)
• An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study (Q85232838) (← links)
• Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors (Q90239449) (← links)